- Home
- / Neoleukin Therapeutics
Neoleukin Therapeutics
Stock Price
$3.5
2023-12-19
Market Capitalization
$8.2 M
2023-12-19
Revenue
$925 K
FY, 2024
Neoleukin Therapeutics Summary
Company Summary
- Overview
- Neoleukin Therapeutics is a company developing medicines to treat immunological disorders, such as cancer and autoimmunity. It utilizes various computational methods to build therapeutic proteins.
- Type
- Public
- Status
- Active
- Founded
- 2019
- HQ
- Seattle, WA, US | view all locations
- Website
- https://www.neoleukin.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Erin Lavelle, Board Member
Sarah Noonberg, Board Member
Todd Simpson, Board Member
LocationsView all
2 locations detected
Seattle, WA HQ
United States
1616 Eastlake Ave E #360
Seattle, WA
United States
188 E Blaine St #450
Neoleukin Therapeutics Financials
Summary Financials
- Cash (Q1, 2026)
- $124.2M
- EBIT (Q1, 2026)
- ($33.3M)
- Enterprise value
- ($106.8M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026